Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2023 Apr 7;136(12):1491–1493. doi: 10.1097/CM9.0000000000002636

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

PMC Copyright notice

Treatment responses for NHL patients who were treated with Chi-BEAC conditioning regimen and ASCT for 53 B-NHL (A) and for 16 T-NHL (B). CR1/PR1^*: Patients who underwent upfront ASCT; CR/PR >1^†: Patients who underwent salvage ASCT. ASCT: Autologous stem cell transplantation; BEAC: Carmustine, etoposide, cytarabine, and cyclophosphamide; Chi-BEAC: Chidamide-BEAC; CMR: Complete metabolic remission; CR: Complete remission; NHL: Non-Hodgkin lymphoma; PD: Progressive disease; PR: Partial remission.